Research Roundup

Debbie Rigby looks at the latest in research news Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes This review provides an expert opinion on dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. Dapagliflozin and other SGLT2

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Forum: Meningococcal vaccine
Next Hidden population at thunderstorm asthma risk